Caroline Gaudy - Publications

RIPOR2 promotes multinucleation of melanoma cells downstream of the RAS/ERK oncogenic pathway.

Journal: iScience

Published: June 27, 2025

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

Journal: Annales de dermatologie et de venereologie

Published: February 07, 2023

Allergy activity in the dermatology department of a French university hospital over a 2-year period: A retrospective study of 1813 patients.

Journal: Annales de dermatologie et de venereologie

Published: November 07, 2022

The value of pharmaceutical expertise in the detection and management of drug interactions with targeted therapies in melanoma.

Journal: Annales de dermatologie et de venereologie

Published: June 25, 2022

Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.

Journal: The journal of allergy and clinical immunology. In practice

Published: September 15, 2021

Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: December 03, 2019

Reduced H3K27me3 Expression is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules.

Journal: The American journal of surgical pathology

Published: January 26, 2018

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes.

Journal: Diabetes care

Published: June 29, 2015

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.

Journal: European journal of endocrinology

Published: November 23, 2014

(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: November 23, 2013